Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab + ICE in Pediatric Recurrent/Refractory B-cell NHL and B-ALL
NCT00058461Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Nov 2003
- Primary completion
- Mar 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of rituximab in non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL), sponsored by National Cancer Institute. Primary endpoints: Response rate determined by physical exam and appropriate imaging studies up to 3 years, Relapse-free survival rate up to 3 years and 1 more. Started Nov 2003; status: terminated.
02
Drugs
rituximab
03
Conditions
non-Hodgkin lymphoma (NHL)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00058461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00058461.